BODIPY-Based Photothermal Agent Incorporating Azulene for Enhanced NIR Absorption and Tumor Ablation
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Kai Nishimura und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan. Hauptthemen laut MEDLINE: Azulenes, Boron Compounds, Photothermal Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Core Research for Evolutional Science and Technology, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Photothermal therapy (PTT) is a promising minimally invasive treatment that converts light energy into localized heat for tumor ablation. Indocyanine green (ICG), the only clinically approved photothermal agent (PTA), suffers from rapid photobleaching and poor tumor retention, underscoring the urgent need for next-generation PTAs with improved properties. In this study, we report AzuGlu-BODIPY, a novel azulene-containing BODIPY-based PTA incorporating 1,2,3,4-tetrahydroquinoline and glucose, designed to overcome these limitations. AzuGlu-BODIPY demonstrates a high photothermal conversion efficiency (PCE) of 51%, effective near-infrared (NIR) absorption, and thermal stability in both dimethyl sulfoxide (DMSO) and aqueous solutions. In vitro studies revealed potent photothermal efficacy against cancer cell lines, with IC50 values of 3.1-4.6 μM under 808 nm laser irradiation, while in vivo experiments showed complete tumor regression in 4T1 tumor-bearing mice following localized administration and laser treatment. These results suggest AzuGlu-BODIPY as a promising PTA and provide a versatile platform for advancing azulene-based PTAs with enhanced functionality for PTT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
- School of Materials and Chemical Technology, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
- Laboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
- Research Center for Autonomous Systems Materialogy (ASMat), Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
ORCID-Profile: Tomoya Fukui, Kazuki Miura, Satoshi Okada, Takanori Fukushima, Hiroyuki Nakamura
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Core Research for Evolutional Science and Technology
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Nishimura, K., Kato, M., Fukui, T., Miura, K., Tsuda, M., Okada, S., Fukushima, T., & Nakamura, H. (2025). BODIPY-Based Photothermal Agent Incorporating Azulene for Enhanced NIR Absorption and Tumor Ablation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00071
Vancouver
Nishimura K, Kato M, Fukui T, Miura K, Tsuda M, Okada S, et al. BODIPY-Based Photothermal Agent Incorporating Azulene for Enhanced NIR Absorption and Tumor Ablation. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00071
BibTeX
@article{Nishimura2025,
author = {Nishimura, Kai and Kato, Mikiya and Fukui, Tomoya and Miura, Kazuki and Tsuda, Masato and Okada, Satoshi and Fukushima, Takanori and Nakamura, Hiroyuki},
title = {BODIPY-Based Photothermal Agent Incorporating Azulene for Enhanced NIR Absorption and Tumor Ablation},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00071}
}
EUVIMED